An older couple, seen from behind, walks along an autumn avenue of plane trees in a park.

For patients and families in the Western Balkans

Just diagnosed with lung cancer?

You don’t have to understand everything today. Here you’ll find calm, clear information about lung cancer, both non-small cell and small cell, in your language and with help in your country.

  • In your language
  • A source for every fact
  • No sign-up, no cookies

My path

What lies ahead for me?

Three questions, and you see your path: tests, treatments, your questions for the appointment.

Find my path

Nothing is stored or sent.

1Which type of lung cancer is it?

What happens next

The path after diagnosis

This is how it usually goes.

  1. ScansA CT or PET-CT shows where something looks unusual.
  2. BiopsyA small tissue sample is taken.
  3. PathologyType and stage are determined.
  4. Biomarker testThe tumour is tested for gene changes and PD-L1.
  5. Tumour boardSpecialists discuss your case together.
  6. TreatmentTreatment starts, with regular check-ups.

Questions you can ask at each stepThe order can differ.

Living with it

It all revolves around you

Besides treatment, many parts of your life matter. For each one you will find calm, practical advice.

Go to Living with it

Treatment

How treatment is organised

In advanced NSCLC, treatments follow one another in lines. Clinical trials and supporting treatments can be added at any time.

  1. First lineThe first treatment
    • Targeted tabletWhen the test finds a matching change, for example EGFR, ALK or ROS1.
    • Immunotherapy aloneWithout such a change, when PD-L1 is high (50% or more).e.g. pembrolizumab, cemiplimab, atezolizumab
    • Immunotherapy with chemotherapyWithout such a change, at any PD-L1 level. This also applies with KRAS G12C.e.g. platinum chemotherapy with pembrolizumab
    The test result helps decide
  2. Second lineIf the cancer grows again
    • Targeted tablet used only nowFor some changes it is authorised in the EU only after a first treatment, above all KRAS G12C.for KRAS G12C: sotorasib or adagrasib
    • Next targeted treatmentWhen the first tablet stops working. A new test sometimes shows what has changed.
    • ChemotherapyWhen no targeted treatment fits. After immunotherapy alone, often with platinum.e.g. docetaxel
    This is where KRAS G12C matters
  3. Third lineFurther options
    • What has not been given yetFor example a targeted tablet after chemotherapy, or the other way round.
    • Clinical trialNew medicines and combinations are being tested, including newer KRAS inhibitors.
    • Focus on comfortWhen further medicines would burden more than help. You decide this together with your team.
    Decided again, together
Clinical trialsPossible at every line. Ask about them early.

Alongside, when it helps

  • RadiotherapyAimed at single spots, or to ease symptoms.
  • SurgeryMainly in early stages, when the tumour can be removed completely.
  • Supportive careFor pain, breathlessness and nausea. Always, from the start.

Simplified overview for advanced non-small cell lung cancer (NSCLC), as of November 2026. The examples are substances, not a recommendation. Your care team decides with you what fits and what is available in your country. Small cell lung cancer is treated differently.
Sources: ESMO, Onkopedia, EMA sotorasib, EMA adagrasib, review on KRAS G12C

More about treatment